Video

Expert Advises Patients with CLL on Three Things They Should Be Aware of To Maximize the Benefit of Upfront Treatment

In an interview with CURE®, Dr. Mazyar Shadman discussed ways that patients with chronic lymphocytic leukemia can play a role in ensuring that they are able to reap the benefits of treatment.

Patients with chronic lymphocytic leukemia must remain observant and report any side effects, especially if they are serious, to ensure that they get the most out of their upfront treatment, according to Dr. Mazyar Shadman.

In an interview with CURE®, Shadman, of Seattle Cancer Care Alliance and Fred Hutchinson Cancer Center, discussed ways that patients can play a role in ensuring that they are able to reap the benefits of treatment.

Transcription:

First of all, they need to be well educated about the potential side effects of this treatment. So, some side effects are more serious. And they need to know that if that happens, they need to call the physician or the team as soon as possible. For example, if you're on a Bruton tyrosine kinase inhibitor, and you know (there’s) bleeding, you need to notify your physician. So, just be aware of side effects and know that some of them are more urgent and others are not, but make sure you are in communication with your team.

These days, we have a lot of options we can (use), using BTK inhibitors as an example, we have now next generation BTK inhibitors that are basically better tolerated so we can always switch treatment to one of the novel ones or maybe even change the class to a completely different type of therapy.

Number one would be knowing the side effects. Number two (is) just knowing what to expect, again, a lot of times, it's not uncommon for patients who; we do get a lot of the second opinions and consults. And they just didn't know that this treatment, for example, is not supposed to be stopped. They're like, ‘Oh, I'm taking a nap for a year.’ So, give a realistic expectation to the patient on what to expect from a drug like ibrutinib or acalabrutinib … or duvelisib if you're in the relapsed setting. Also, with venetoclax, just give the realistic expectation (that) yes, we do give the treatment for one year, but I can't promise that at the end of one year, if I stop, you'll be in remission for years, right? It depends on how good (you respond) to the treatment. So, number two would be giving realistic expectations (and) number three … goes back to this principle of a doctor-patient relationship and we have to come up with a plan that both are comfortable with. Some patients just feel safer to be watched a little bit more closely and some don't.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.